busulfan has been researched along with Cross Infection in 2 studies
Cross Infection: Any infection which a patient contracts in a health-care institution.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silva, AMPSD | 1 |
| Barbosa, LC | 1 |
| Marques, LMA | 1 |
| Carreira, LY | 1 |
| Fonseca, FMCD | 1 |
| Lima, APC | 1 |
| Sodré, JJM | 1 |
| Pignati, LT | 1 |
| Araújo, OR | 1 |
| Silva, DCBD | 1 |
| Carlesse, FAMC | 1 |
| Rauenzahn, S | 1 |
| Truong, Q | 1 |
| Cumpston, A | 1 |
| Goff, L | 1 |
| Leadmon, S | 1 |
| Evans, K | 1 |
| Zhang, J | 1 |
| Wen, S | 1 |
| Craig, M | 1 |
| Hamadani, M | 1 |
| Kanate, AS | 1 |
2 other studies available for busulfan and Cross Infection
| Article | Year |
|---|---|
A case-control study of Clostridioides difficile symptomatic infections in a pediatric cancer hospital.
Topics: Anti-Bacterial Agents; Asparaginase; Busulfan; Cancer Care Facilities; Carboplatin; Case-Control Stu | 2023 |
Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Cross Infection; Female; Graft vs Host Disease; Health Care Costs | 2014 |